BiotechTube
AIRNA

AIRNA

Hamburg, Germany· Est.
airna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $253.6M

Overview

AIRNA is a private, pre-clinical stage biotech focused on developing RNA editing therapeutics for a broad range of diseases. The company is building a robust leadership team with recent C-suite appointments and is backed by a strong syndicate of top-tier life science investors. While its technology holds transformative potential, AIRNA faces significant risks common to platform biotechs, including unproven clinical translation and intense competition in the nucleic acid therapeutics space.

OncologyRare Diseases

Technology Platform

RNA editing platform for precise, single-base correction of RNA transcripts to develop functional cures for genetic diseases.

Funding History

5
Total raised:$253.6M
Series B$155M
Series A$60M
PIPE$30M
Seed$4.3M

Opportunities

RNA editing represents a vast market opportunity, enabling potential cures for thousands of rare genetic diseases and modulation of high-prevalence common diseases.
The proven success of other RNA modalities (mRNA, siRNA) creates a receptive clinical and regulatory environment for this next-generation approach.

Risk Factors

The technology is unproven in humans, facing challenges with delivery, efficiency, and durability.
The company operates in an intensely competitive landscape with well-funded rivals and faces significant execution risk as it transitions from pre-clinical research to clinical development.

Competitive Landscape

AIRNA competes in the emerging RNA editing field against companies like Wave Life Sciences, Korro Bio, and Shape Therapeutics (Roche), as well as large pharma internal programs. Success will depend on demonstrating superior editing efficiency, specificity, and delivery compared to these platforms.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →